| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11095-008-9823-9 |
| P698 | PubMed publication ID | 19184618 |
| P50 | author | Aleksandra Galetin | Q43767899 |
| P2093 | author name string | J Brian Houston | |
| Helen E Cubitt | |||
| P2860 | cites work | Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract | Q28200110 |
| Simulation and prediction of in vivo drug metabolism in human populations from in vitro data | Q28286115 | ||
| The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes | Q28365923 | ||
| Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. | Q30583202 | ||
| Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches | Q30984976 | ||
| A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes | Q30991281 | ||
| Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant | Q31012256 | ||
| Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. | Q31096663 | ||
| Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction | Q31146882 | ||
| Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes | Q33373620 | ||
| Is the role of the small intestine in first-pass metabolism overemphasized? | Q33650100 | ||
| Pharmacokinetics of raloxifene and its clinical application | Q33700669 | ||
| Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. | Q34403276 | ||
| Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate | Q34448146 | ||
| The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism*† | Q34479006 | ||
| In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine | Q35804150 | ||
| Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios | Q35860313 | ||
| Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? | Q35956848 | ||
| UDP-glucuronosyltransferases and clinical drug-drug interactions | Q36076337 | ||
| In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises | Q36385207 | ||
| The human intestinal cytochrome P450 "pie". | Q36420382 | ||
| Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. | Q36535786 | ||
| Intestinal UGTs as potential modifiers of pharmacokinetics and biological responses to drugs and xenobiotics | Q36725226 | ||
| Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance | Q36750350 | ||
| Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions | Q36851934 | ||
| Quercetin pharmacokinetics in humans | Q38502477 | ||
| The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. | Q39999160 | ||
| Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds | Q40100581 | ||
| Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations | Q40488412 | ||
| In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance | Q43926234 | ||
| Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance | Q43999040 | ||
| Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. | Q44217898 | ||
| Utility of Hepatocytes in Predicting Drug Metabolism: Comparison of Hepatic Intrinsic Clearance in Rats and Humans in Vivo and in Vitro | Q44403620 | ||
| The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases | Q44447150 | ||
| Disposition mechanisms of raloxifene in the human intestinal Caco-2 model | Q44799767 | ||
| An investigation of human and rat liver microsomal mycophenolic acid glucuronidation: evidence for a principal role of UGT1A enzymes and species differences in UGT1A specificity | Q44912290 | ||
| The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants | Q44982057 | ||
| N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7. | Q45006164 | ||
| Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration | Q46363542 | ||
| Altered AZT (3'-azido-3'-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment | Q46622506 | ||
| Quantitative regioselectivity of glucuronidation of quercetin by recombinant UDP-glucuronosyltransferases 1A9 and 1A3 using enzymatic kinetic parameters | Q46879949 | ||
| The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver | Q48577929 | ||
| Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism | Q51530623 | ||
| Interaction of human serum albumin with the electrophilic metabolite 1-O-gemfibrozil-beta-D-glucuronide. | Q51553942 | ||
| Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations | Q51898036 | ||
| In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. | Q52079646 | ||
| Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance | Q53013898 | ||
| Pharmacokinetics of intravenous salbutamol in renal insufficiency and its biological effects | Q54455366 | ||
| Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass Metabolism | Q61910691 | ||
| Microsomal prediction ofin vivoclearance and associated interindividual variability of six benzodiazepines in humans | Q61910693 | ||
| The pharmacokinetics of diclofenac sodium following intravenous and oral administration | Q66985119 | ||
| Pharmacokinetics and absolute bioavailability of salbutamol in healthy adult volunteers | Q69397320 | ||
| Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine | Q69910240 | ||
| Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation | Q79609080 | ||
| Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement | Q82903863 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 1073-1083 | |
| P577 | publication date | 2009-01-31 | |
| P1433 | published in | Pharmaceutical Research | Q7180737 |
| P1476 | title | Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance | |
| P478 | volume | 26 |
| Q38661092 | A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration. |
| Q36132276 | Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches |
| Q30585329 | Application of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data |
| Q38798449 | Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG. |
| Q38799423 | Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance. |
| Q45345117 | Challenges and Opportunities with Predicting in Vivo Phase II Metabolism via Glucuronidation from in Vitro Data |
| Q35846898 | Characterization of In Vitro Glucuronidation Clearance of a Range of Drugs in Human Kidney Microsomes: Comparison with Liver and Intestinal Glucuronidation and Impact of Albumin |
| Q33753957 | Characterization of Raloxifene Glucuronidation: Potential Role of UGT1A8 Genotype on Raloxifene Metabolism In Vivo |
| Q30661362 | Combining in vitro embryotoxicity data with physiologically based kinetic (PBK) modelling to define in vivo dose-response curves for developmental toxicity of phenol in rat and human. |
| Q84415824 | Contribution of rat intestinal metabolism to the xenobiotics clearance |
| Q40230063 | Development and application of a human PBPK model for bromodichloromethane to investigate the impacts of multi-route exposure. |
| Q90126080 | Dose-dependent naloxone-induced morphine withdrawal symptoms in opioid-dependent males-a double-blinded, randomized study |
| Q24649164 | Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes |
| Q45851514 | Extensive intestinal glucuronidation of raloxifene in vivo in pigs and impact for oral drug delivery |
| Q37600381 | Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination |
| Q83333391 | Human Pharmacokinetic Prediction of UDP-Glucuronosyltransferase Substrates with an Animal Scale-Up Approach |
| Q48110673 | Identification and disposition of novel mono-hydroxyl mefenamic acid and their potentially toxic 1-O-acyl-glucuronides in vivo. |
| Q82227645 | Identification of UDP-Glucuronosyltransferases Responsible for the Glucuronidation of Darexaban, an Oral Factor Xa Inhibitor, in Human Liver and Intestine |
| Q33891027 | In vitro glucuronidation of 2,2-bis(bromomethyl)-1,3-propanediol by microsomes and hepatocytes from rats and humans |
| Q38131859 | In vitro-in vivo extrapolation (IVIVE) for predicting human intestinal absorption and first-pass elimination of drugs: principles and applications. |
| Q37920916 | In vitroandin vivosmall intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences |
| Q48177006 | Inhibition of glucuronidation and oxidative metabolism of buprenorphine using GRAS compounds or dietary constituents/supplements: in vitro proof of concept |
| Q83465244 | Metabolism of the c-Fos/Activator Protein-1 Inhibitor T-5224 by Multiple Human UDP-Glucuronosyltransferase Isoforms |
| Q84023351 | Method for predicting human intestinal first-pass metabolism of UGT substrate compounds |
| Q87276120 | Methylation, Glucuronidation, and Sulfonation of Daphnetin in Human Hepatic Preparations In Vitro: Metabolic Profiling, Pathway Comparison, and Bioactivity Analysis |
| Q33588394 | Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic Clearance |
| Q35961995 | Milk Thistle Constituents Inhibit Raloxifene Intestinal Glucuronidation: A Potential Clinically Relevant Natural Product-Drug Interaction |
| Q33628703 | Optimization of intestinal microsomal preparation in the rat: A systematic approach to assess the influence of various methodologies on metabolic activity and scaling factors. |
| Q33938740 | Oxycodone/Naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrence |
| Q38951944 | Physiologically based kinetic modeling of hesperidin metabolism and its use to predict in vivo effective doses in humans. |
| Q34633431 | Physiologically-based toxicokinetic modeling of zearalenone and its metabolites: application to the Jersey girl study |
| Q26764739 | Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models |
| Q34006083 | Prediction of the Intestinal First-pass Metabolism of CYP3A and UGT Substrates in Humans from in vitro Data |
| Q38017309 | Probe ADME and Test Hypotheses: a PATH beyond clearancein vitro–in vivocorrelations in early drug discovery |
| Q42289931 | Quantifying gut wall metabolism: methodology matters |
| Q34299302 | Quantitative Prediction of Human Intestinal Glucuronidation Effects on Intestinal Availability of UDP-Glucuronosyltransferase Substrates Using In Vitro Data |
| Q36070644 | Quantitative determination of buprenorphine, naloxone and their metabolites in rat plasma using hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry |
| Q36595916 | Quantitative prediction and clinical evaluation of an unexplored herb-drug interaction mechanism in healthy volunteers. |
| Q46689359 | Raloxifene glucuronidation in liver and intestinal microsomes of humans and monkeys: contribution of UGT1A1, UGT1A8 and UGT1A9. |
| Q38107441 | Recent results in alamethicin research. |
| Q86208890 | Significance of Reductive Metabolism in Human Intestine and Quantitative Prediction of Intestinal First-Pass Metabolism by Cytosolic Reductive Enzymes |
| Q45746344 | Stereoselective Glucuronidation of Ornidazole in Humans: Predominant Contribution of UDP-Glucuronosyltransferases 1A9 and 2B7 |
| Q43268650 | The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potentia |
| Q38176051 | The role of drug metabolizing enzymes in clearance |
| Q48308026 | The use of isolated enterocytes to study Phase I intestinal drug metabolism: validation with rat and pig intestine. |
| Q53630136 | Unequivocal evidence supporting the segregated flow intestinal model that discriminates intestine versus liver first-pass removal with PBPK modeling. |
| Q45949994 | Use of a Multistaged Time-Dependent Inhibition Assay to Assess the Impact of Intestinal Metabolism on Drug-Drug Interaction Potential |
| Q43730577 | Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans |
Search more.